# Value Proposition Analysis: What We Offer vs. What We Know

**Date:** January 28, 2025  
**Critical Reality Check**

---

## 1. WHAT WE KNOW ABOUT THE PIs

### ✅ What We Have:
- **PI Names** (28)
- **Institutions** (28)
- **NCT IDs** (28)
- **Trial Titles** (from ClinicalTrials.gov)
- **Trial Phase** (Phase 1, 2, 3, etc.)
- **Enrollment Numbers** (if available)
- **Interventions** (treatment drugs)
- **Trial Status** (RECRUITING, ACTIVE_NOT_RECRUITING)
- **Start/Completion Dates**

### ❌ What We DON'T Know:
- **Email addresses** (0 found)
- **Their specific research focus** (beyond trial)
- **Publication history** (have they published on CA-125/KELIM?)
- **Current data availability** (do they have data ready to share?)
- **Data sharing policies** (institution restrictions?)
- **Collaboration history** (do they share data?)
- **Knowledge of KELIM** (have they heard of it?)
- **Institutional requirements** (IRB, data use agreements)

---

## 2. WHAT VALUE DO WE OFFER THEM?

### ✅ Genuine Value Propositions:

#### **1. Co-Authorship on Publication**
- **Value:** Medium-High
- **Reality:** They contribute data, get authorship
- **Appeal:** Academic researchers value publications
- **Certainty:** Can deliver if validation succeeds

#### **2. Access to Validated Biomarker**
- **Value:** Medium
- **Reality:** If validated, they can use KELIM in their research
- **Appeal:** Useful for future studies
- **Certainty:** Depends on validation success

#### **3. Contribution to Field**
- **Value:** Low-Medium
- **Reality:** Advancing ovarian cancer treatment
- **Appeal:** Intrinsic motivation
- **Certainty:** Always true

#### **4. Recognition**
- **Value:** Low-Medium
- **Reality:** Acknowledgment in validation study
- **Appeal:** Professional recognition
- **Certainty:** Can deliver

### ❌ What We CAN'T Offer:
- **Funding** (no money to offer)
- **Guaranteed publication venue** (don't know where it will be published)
- **Timeline certainty** (validation may take time)
- **Exclusive access** (others may validate too)
- **Immediate results** (validation takes months)

---

## 3. HONEST ASSESSMENT

### **Weaknesses in Current Approach:**

1. **Limited Personalization**
   - We don't know their specific research interests
   - We don't know if they care about biomarkers
   - We don't know their publication priorities

2. **Unclear Value for Them**
   - Co-authorship is good, but not unique
   - They may already have their own analyses
   - They may not see immediate benefit

3. **No Relationship Building**
   - Cold outreach (no prior relationship)
   - No introduction or mutual connection
   - No context about why we're reaching out

4. **Missing Information**
   - Don't know if they have data ready
   - Don't know their data sharing policies
   - Don't know their collaboration history

---

## 4. HOW TO IMPROVE VALUE PROPOSITION

### **Before Outreach - Research Each PI:**

1. **PubMed Search**
   - Find their publications
   - See if they've published on CA-125, biomarkers, or KELIM
   - Understand their research focus

2. **Institution Research**
   - Check their institution's data sharing policies
   - Look for collaboration history
   - Check if they have data repositories

3. **Trial Deep Dive**
   - Understand their specific trial design
   - Check enrollment numbers
   - See if trial is completed (data may be ready)

4. **Network Analysis**
   - Check for mutual connections
   - See if they've collaborated with others
   - Find introduction opportunities

### **Enhanced Value Propositions:**

#### **1. Specific Research Alignment**
- "I noticed you published on [specific topic] - this aligns with KELIM validation"
- "Your trial [specific design] is ideal for this validation"

#### **2. Mutual Benefit Emphasis**
- "This validation will strengthen the evidence base for your ongoing research"
- "KELIM could enhance your trial's biomarker analysis"

#### **3. Low Burden, High Impact**
- "You already have the data - we just need to analyze it"
- "Minimal effort on your part, significant contribution to the field"

#### **4. Timeline and Process Clarity**
- "We can work around your schedule"
- "We'll handle all analysis and manuscript writing"
- "You just need to share data - we do the rest"

---

## 5. REVISED OUTREACH STRATEGY

### **Phase 1: Research (Before Outreach)**
1. **For each PI:**
   - Search PubMed for their publications
   - Check their institution website
   - Review their trial details
   - Look for mutual connections

2. **Create PI Profiles:**
   - Research focus
   - Publication history
   - Collaboration patterns
   - Data sharing likelihood

### **Phase 2: Prioritization**
1. **High Priority:**
   - PIs who have published on biomarkers/CA-125
   - Completed trials (data ready)
   - Academic institutions (more likely to collaborate)
   - Larger trials (more patients)

2. **Medium Priority:**
   - Active trials (data may be available)
   - Industry-sponsored (may have restrictions)

3. **Low Priority:**
   - Early phase trials (may not have outcomes yet)
   - Very small trials (<50 patients)

### **Phase 3: Personalized Outreach**
1. **Customize each email:**
   - Reference their specific research
   - Mention their publications (if relevant)
   - Align with their trial design
   - Show you've done your homework

2. **Clear Value Statement:**
   - What's in it for them (specific to their situation)
   - Why their data is valuable (specific reasons)
   - How this helps their research (specific benefits)

---

## 6. HONEST VALUE PROPOSITION TEMPLATE

### **What We Can Genuinely Offer:**

```
**What's In It For You:**

1. **Co-Authorship** - You'll be a co-author on the validation publication
   (assuming validation is successful and manuscript is accepted)

2. **Biomarker Access** - If validated, you'll have access to KELIM for your research
   (useful for future studies and analyses)

3. **Field Contribution** - Your data will contribute to advancing ovarian cancer treatment
   (helping validate a promising biomarker)

4. **Low Burden** - We handle all analysis and manuscript writing
   (you just need to share data - we do the rest)

5. **Flexible Timeline** - We can work around your schedule and data availability
   (no rush, we understand data sharing takes time)
```

### **What We Can't Guarantee:**

- Publication venue or impact factor
- Exact timeline (depends on validation results)
- Exclusive access (others may validate too)
- Funding or financial compensation

---

## 7. RECOMMENDATIONS

### **Before Sending Emails:**

1. **Research Each PI** (2-3 hours per PI)
   - PubMed search
   - Institution research
   - Trial analysis
   - Network check

2. **Create PI Profiles** (document findings)
   - Research focus
   - Publications
   - Collaboration likelihood
   - Data availability estimate

3. **Prioritize Contacts**
   - Start with highest likelihood of success
   - Focus on those with completed trials
   - Prioritize academic institutions

4. **Personalize Heavily**
   - Reference their research
   - Mention specific publications
   - Align with their interests
   - Show genuine interest in their work

### **Alternative Approach:**

**Consider reaching out to:**
1. **KELIM developers** (if known) - they may have connections
2. **Institut Curie** (mentioned in validation requirements) - they developed KELIM
3. **Trial consortia** (NRG, GCIG, AGO) - may have pooled data
4. **Authors of KELIM papers** - they may know who has data

---

## 8. REALISTIC EXPECTATIONS

### **Success Probability:**
- **Cold outreach to unknown PIs:** 10-20% response rate
- **Personalized outreach with research:** 20-30% response rate
- **Warm introduction:** 40-60% response rate

### **Data Sharing Rate:**
- **Of those who respond:** 30-50% may share data
- **Overall:** 3-7 datasets from 28 contacts (realistic)

### **Timeline:**
- **Research phase:** 1-2 weeks
- **Outreach phase:** 1 week
- **Response wait:** 1-2 weeks
- **Data sharing negotiation:** 2-4 weeks
- **Total:** 5-9 weeks to get data

---

## CONCLUSION

**Current State:**
- We have **basic information** (names, institutions, trials)
- We have **limited value proposition** (co-authorship, biomarker access)
- We have **no relationships** (cold outreach)

**To Improve:**
- **Research each PI** before outreach
- **Personalize heavily** based on their research
- **Emphasize mutual benefit** specific to their situation
- **Consider alternative approaches** (KELIM developers, consortia)

**Reality:**
- Cold outreach has **low success rate** (10-20%)
- Need to **invest time in research** to improve odds
- Consider **warm introductions** if possible
- May need to **adjust expectations** or approach

---

**Last Updated:** January 28, 2025





